Danish manufacturing firm breaks ground in Peachtree City; 200 new jobs expected

By The Citizen-August 22, 2023

Meditec groundbreaking in Georgia

SP Meditec recently broke ground on a 120,000 square foot, state-of-the-art manufacturing facility that is expected to create 200 new jobs in Peachtree City.

The plant, which will be located off Georgia State Route 74, is scheduled to begin operations in August 2024.

Several factors played into SP Meditec’s selection of Peachtree City for their company’s US expansion. Peter Fejfer, Managing Director for the Denmark-based business, cited the south metro Atlanta community’s proximity to the world’s busiest airport, skilled workforce, and strategic location as reasons behind the decision.

“We aim to tap into Peachtree City’s talented pool of professionals and contribute to the local economy,” Fejfer stated.

SP Meditec develops, manufactures, and assembles plastic solutions for the healthcare industry. Their Peachtree City expansion marks a significant milestone in the company’s strategy and commitment to meeting the growing demand for high-quality injection molded parts worldwide.

“I’m excited to welcome SP Meditec to Peachtree City,” Mayor Kim Learnard said. “This major investment in our city not only underscores our dedication to fostering smart growth and innovation, but also solidifies Peachtree City’s position as a hub for cutting-edge advancements in the healthcare sector.”

Dividend Realty is acting as project developer for the new plant. Their subsidiary, Dividend ECS, will design the facility. Davis Construction will serve as the facility’s construction manager.

“We look forward to completing the project and are committed to continuing our growth in this new market,” Fejfer continued.

Georgia’s Life Sciences Momentum is Getting Noticed Nationally.

August 21, 2026
Genetic Engineering & Biotechnology News (GEN) has named Georgia #4 among its “Next 5 States” for emerging U.S. biopharma clusters . The article highlights UCB’s planned $2 billion investment at in Gwinnett County, Micron Biomedical’s new Alpharetta facility, Manus Bio’s expansion in Augusta, Science Square, Emory University, the CDC — and Georgia Life Sciences’ 10-year Life Sciences Roadmap . This recognition is exciting. But even more importantly, it validates the work happening across our entire ecosystem — and perfect momentum as we head into the 2026 Georgia Life Sciences Summit next week. Read more by visiting: Next 10 U.S. Biopharma Clusters

BIO Supports PDUFA VIII Commitment Letter and Urges Timely Reauthorization

August 17, 2026
Biotechnology Innovation Organization (BIO) Senior Vice President of Science & Regulatory Affairs Annetta Beauregard issued the following statement on the release of the Prescription Drug User Fee Act (PDUFA) VIII commitment letter: “For more than 30 years, PDUFA has helped deliver hundreds of new medicines to American patients. As a lead industry negotiator for the PDUFA VIII agreement, BIO supports the PDUFA VIII commitment letter and its strengthening of regulatory review, advancing innovation, and helping deliver safe and effective treatments to patients. “Specifically, the PDUFA VIII agreement includes important commitments that bolster the FDA’s core review activities, ensure accountability for predictable performance, improve financial sustainability and improve communication, transparency and efficiency. “Timely, bipartisan reauthorization of PDUFA is vital for protecting the health of Americans, strengthening U.S. competitiveness, and maintaining America’s global leadership in medical innovation. BIO is committed to working with Congress to ensure reauthorization by September 30, 2027.” The FDA has announced plans to hold a hybrid public meeting at 9am on 9/16 to discuss the proposed enhancements for the reauthorization of PDUFA for fiscal years (FYs) 2028 through 2033. Learn More about PDUFA and the PDUFA VIII commitment letter HERE .

Georgia Life Sciences Submits Comments on Medicare Drug Price Negotiation Program

August 17, 2026
Representing Georgia’s life sciences community, GLS emphasized the importance of advancing policies that improve affordability and patient access while preserving the environment necessary for continued biomedical innovation. In its comments, GLS urged CMS to maintain a framework grounded in FDA regulatory determinations and raised concerns about how certain proposed policies could affect post-approval research and development, investment in new indications, and patient access to innovative therapies. GLS also encouraged CMS to consider the broader implications for healthcare delivery, including the potential impact on patients and providers in rural and underserved communities. As federal drug pricing policy continues to evolve, Georgia Life Sciences will continue to advocate for approaches that balance affordability, access, and innovation while ensuring Georgia’s life sciences community has a voice in the policymaking process. Read Georgia Life Sciences’ full comments to CMS ( click here ).
MORE POSTS